Date: 2018-05-03
Type of information: Grant
Company: Synpromics (UK)
Investors: Scottish Enterprise (UK)
Amount: £1.9 million
Funding type: grant
Planned used:
- The funds will expand Synpromics’ world leading R&D programmes in gene regulation for cell and gene medicines. This grant is part of Synpromics’ ambitious £5.4 million R&D project which initially creates 11 new high-skilled jobs. Synpromics will use the grant to expand and further develop its PromPT technology platform and to create novel inducible promoter systems that can be applied across the biotechnology sector. The funding will support pre-clinical evaluation studies in a range of disease models, allowing the company to identify the best use of its technology for the treatment of disease using advanced therapeutic regimes such as cell and gene medicine.
- Synpromics' technology is currently being evaluated in over 25 product development pipelines in pharmaceutical, biopharmaceutical and biotechnology companies worldwide, targeting diseases such as Parkinson’s, haemophilia, muscular dystrophies and liver disorders.
Others:
- • On May3, 2018, Synpromics, a leader in gene control, announced it has been awarded a £1.9m research and development grant from Scottish Enterprise. The funds will expand Synpromics’ world leading R&D programmes in gene regulation for cell and gene medicines.
Therapeutic area: Technology - Services
Is general: Yes
